ANCA vasculitis: time for a change in treatment paradigm? Not yet.
(25/99)
(+info)
Valvular involvement in ANCA-associated systemic vasculitis: a case report and literature review.
(26/99)
(+info)
In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations.
(27/99)
(+info)
Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis.
(28/99)
(+info)
Kaposi's sarcoma following immunosuppressive therapy for vasculitis.
(29/99)
Kaposi's sarcoma (KS) is widely reported to develop after renal transplantation and is induced by activation of a latent human herpes virus 8. We report the clinical features and outcome of a 50-year-old woman who presented with KS 18 weeks after starting immunosuppressive therapy for vasculitis. She had positive-titer IgG antibody to human herpes virus 8. Cyclophosphamide pulses were interrupted, and prednisone was decreased gradually to 10 mg/day. Skin lesions showed important regression with stabilization of the general state and renal function. Eight months later, the patient presented with a diffuse cutaneous KS that required the discontinuation of steroids. Within 1 month, her general status and renal function deteriorated, and she died with a disseminated intravascular coagulation syndrome. (+info)
Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis.
(30/99)
(+info)
Epigenetics and complementary proteins.
(31/99)
(+info)
Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.
(32/99)
(+info)